From missed diagnosis to lifelong survivorship: a precision oncology roadmap for equity in pediatric and AYA cancer care
- 1Department of Biomedical and Laboratory Science, Africa University
- 2Department of Molecular Medicine and Haematology, University of the Witwaterarand
- 3Department of Hematology and Immunohematology, Bahir Dar University
Abstract
Cancer in children, adolescents, and young adults (AYA) remains a global health challenge, with disparities in survival and quality of life between high-resource and low- and middle-income countries (LMICs). These disparities arise across the cancer continuum, including delayed recognition, inadequate diagnostic capacity, fragmented referral pathways, treatment abandonment, limited supportive care, unequal access to molecular diagnostics, and insufficient survivorship services. Precision oncology provides an opportunity to address these challenges, but its equity potential extends beyond genomic sequencing and targeted therapies. This narrative review examines an integrated precision oncology continuum encompassing early recognition, diagnostic and pathological accuracy, molecular characterization, risk stratification, precision treatment, response monitoring, supportive care, and lifelong survivorship. Evidence from LMIC settings is used to illustrate diagnostic delay, referral barriers, treatment abandonment, health-system limitations, and outcome disparities without attempting an exhaustive country comparison. The review proposes a tiered, equity-centered framework in which foundational cancer services are strengthened alongside progressively accessible molecular and digital technologies. Regional referral networks, patient navigation, tele-oncology, pathology and laboratory networks, targeted molecular testing, multidisciplinary care, survivorship planning, and longitudinal cancer registries are emphasized as practical components. For AYA patients, fertility, reproductive health, mental health, education, employment, and transition between pediatric and adult services are incorporated into precision care. Ultimately, equitable precision oncology should connect biological precision with health-system precision, ensuring that every young person can receive timely diagnosis, appropriate treatment, continuous monitoring, and lifelong survivorship support.
Related
- Rapid whole-genome sequencing in the pediatric intensive care unit: from etiologic diagnosis to precision management—a narrative review
- A multimodal precision oncology platform integrating genomics,single-cell transcriptomics, and functional drug screening expandstherapeutic options in pediatric brain tumors
- Refining Lung Cancer Care: The Emerging Role of Liquid Biopsy in Screening, Diagnosis, and Precision Oncology.
- Multimodal AI in Hepatocellular Carcinoma: Bridging Diagnosis, Therapy and Prognosis Toward Precision Oncology.
- Comparative Genomic and Epigenetic Landscape of Histone H3.3 G34R and K27M-Mutated Pediatric High-Grade Glioma Suggests Divergent Precision Oncology Strategies
BibTeX
@article{obeagu2026from,
title = {{From missed diagnosis to lifelong survivorship: a precision oncology roadmap for equity in pediatric and AYA cancer care}},
author = {Emmanuel Ifeanyi Obeagu},
journal = {Frontiers in Oncology},
year = {2026},
month = oct,
doi = {10.3389/fonc.2026.1982346},
url = {https://www.frontiersin.org/articles/10.3389/fonc.2026.1982346/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - From missed diagnosis to lifelong survivorship: a precision oncology roadmap for equity in pediatric and AYA cancer care
AU - Emmanuel Ifeanyi Obeagu
PY - 2026
DA - 2026/10/13
JO - Frontiers in Oncology
DO - 10.3389/fonc.2026.1982346
UR - https://www.frontiersin.org/articles/10.3389/fonc.2026.1982346/full
AB - Cancer in children, adolescents, and young adults (AYA) remains a global health challenge, with disparities in survival and quality of life between high-resource and low- and middle-income countries (LMICs). These disparities arise across the cancer continuum, including delayed recognition, inadequate diagnostic capacity, fragmented referral pathways, treatment abandonment, limited supportive care, unequal access to molecular diagnostics, and insufficient survivorship services. Precision oncology provides an opportunity to address these challenges, but its equity potential extends beyond genomic sequencing and targeted therapies. This narrative review examines an integrated precision oncology continuum encompassing early recognition, diagnostic and pathological accuracy, molecular characterization, risk stratification, precision treatment, response monitoring, supportive care, and lifelong survivorship. Evidence from LMIC settings is used to illustrate diagnostic delay, referral barriers, treatment abandonment, health-system limitations, and outcome disparities without attempting an exhaustive country comparison. The review proposes a tiered, equity-centered framework in which foundational cancer services are strengthened alongside progressively accessible molecular and digital technologies. Regional referral networks, patient navigation, tele-oncology, pathology and laboratory networks, targeted molecular testing, multidisciplinary care, survivorship planning, and longitudinal cancer registries are emphasized as practical components. For AYA patients, fertility, reproductive health, mental health, education, employment, and transition between pediatric and adult services are incorporated into precision care. Ultimately, equitable precision oncology should connect biological precision with health-system precision, ensuring that every young person can receive timely diagnosis, appropriate treatment, continuous monitoring, and lifelong survivorship support.
SN - 2234-943X
ER -